Table 6 Treatment responses and outcomes in adults with IgAV-related nephritis

 methylprednisolone pulse treatment, n (%)

11 (4.3)

107 (28.1)

48 (80.0)

P < 0.001^**

 Prednisone/methylprednisolone, n (%)

132 (51.4)

289 (75.9)

53 (88.3)

P < 0.001^**

 prednisone + tripterysium glycosides, n (%)

89 (34.6)

174 (45.7)

9 (15.0)

P < 0.001^**

 prednisone + leflunomide, n (%)

2 (0.8)

12 (3.1)

0 (0)

P = 0.057

 prednisone + mycophenolate mofetil, n (%)

7 (2.7)

59 (15.5)

32 (53.3)

P < 0.001^**

 Follow-up time

55.0 (33.0–74.5)

55.0 (35.0–80.0)

51.5 (34.0–81.2)

P = 0.813

 TA-P (g/d)

0.41 (0.29–0.72)^b

0.45 (0.29–0.73)^c

0.56 (0.40–0.97)

P = 0.003^**

   < 0.4 g/d

122 (47.5)

158 (41.5)

15 (25.0)

P = 0.006^**

  0.4–1.0 g/d

99 (38.5)

160 (42.0)

31 (51.7)

P = 0.171

   > 1.0 g/d

36 (14.0)

63 (16.5)

14 (23.3)

P = 0.203

 TA-RBC (10⁴ cells/mL)

27 (10–64)^a,b

37 (16–91)

58 (20–118)

P = 0.001^**

 TA-MAP (mmHg)

92.3 ± 9.8

91.1 ± 8.6

91.6 ± 8.6

P = 0.240

 Serum creatinine at last follow-up (mg/dL)

0.83 (0.68–1.04)^b

0.82 (0.67–1.06)^c

0.98 (0.72–1.12)

P = 0.088

 50% decline in renal function, n (%)

11 (4.3)

31 (8.1)

8 (13.3)

P = 0.027^*

 ESRD, n (%)

7 (2.7)

20 (5.2)

5 (8.3)

P = 0.114

 ESRD or 50% decline in renal function, n (%)

12 (4.7)

33 (8.7)

8 (13.3)

P = 0.037^*